Coeptis Therapeutics (NASDAQ:COEP) Given Sell (E+) Rating at Weiss Ratings

Key Points

• Weiss Ratings has reissued a "sell (e+)" rating for Coeptis Therapeutics (NASDAQ:COEP), suggesting a negative outlook for the company's stock.
• Coeptis Therapeutics' stock is currently trading down 2.3% at $16.31, after reaching a 1-year low of $2.31 and a high of $19.19.
• The company reported a quarterly loss of ($1.17) EPS with revenue of $0.20 million in its last earnings report on August 14th.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Coeptis Therapeutics Trading Down 2.3%

NASDAQ:COEP traded down $0.38 on Wednesday, reaching $16.31. The company's stock had a trading volume of 34,033 shares, compared to its average volume of 65,454. Coeptis Therapeutics has a 1-year low of $2.31 and a 1-year high of $19.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.83 and a current ratio of 0.83. The firm has a market cap of $78.61 million, a PE ratio of -2.81 and a beta of -0.49. The business's 50-day moving average price is $13.61 and its two-hundred day moving average price is $10.81.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.17) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.